格隆汇1月16日丨智翔金泰(688443.SH)公布，重庆智翔金泰生物制药股份有限公司董事会于近日收到公 司独立董事胡耘通先生递交的书面辞职报告。因工作原因，胡耘通先生申请辞去公司第二届董事会独立 董事，辞职生效后，胡耘通先生将不再担任公司任何职务。 ...

2025年前三季度，智翔金泰实现营业收入2.08亿元，同比增长1,562.05%；实现归属于上市公司股 东的净利润-3.33亿元；实现归属于上市公司股东的扣除非经常性损益的净利润-3.70亿元；经营活动产 生的现金流量净额为-2.61亿元。 (责任编辑：田云绯) 智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为 329,140.14万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6月15 日披露的招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改扩建、 抗体产业化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元（不含税），其中，保荐承销费16,495.98 万元。 智翔金泰已连亏4年3季。2021年至2024年，智翔金泰归属于上市公司股东的净利润分别为-3.22亿 元、-5.76亿元、-8.01亿元、-7.97亿元；归属于上市公司股东的扣非净利润分别为-3.34亿元、-6.45亿 元、-8.13亿元、-8.04亿元。 中国经济网北 ...

风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模96.36亿。今年以来收益10.49%，同 类排名632/5520；近一年收益35.43%，同类排名2508/4203；成立以来收益240.2%。 1月14日，智翔金泰跌2%，截至发稿，报30.80元/股，成交2.05亿元，换手率5.64%，总市值112.94亿 元。智翔金泰股价已经连续3天下跌，区间累计跌幅5.06%。 工银前沿医疗股票A（001717）基金经理为赵蓓。 资料显示，重庆智翔金泰生物制药股份有限公司位于重庆市巴南区麻柳大道699号2号楼A区，成立日期 2015年10月20日，上市日期2023年6月20日，公司主营业务涉及抗体药物的研发、生产与销售。主营业 务收入构成为：销售药品99.96%，其他0.04%。 截至发稿，赵蓓累计任职时间11年61天，现任基金资产总规模172.23亿元，任职期间最佳基金回报 239.8%， ...

Group 1 - The core viewpoint of the news is that Zhixiang Jintai (688443.SH) is currently experiencing a decline in stock price, with a closing price of 31.95 yuan and a drop of 1.51%, indicating it is in a state of loss since its IPO [1] - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with a public offering of 91.68 million shares at an issue price of 37.88 yuan per share [1] - The total amount raised from the IPO was 347.28 million yuan, with a net amount of 329.14 million yuan after deducting issuance costs, which was 68.86 million yuan less than the originally planned amount of 398 million yuan [1] Group 2 - Zhixiang Jintai has reported losses for four consecutive years and three quarters, with net profits attributable to shareholders of -322 million yuan in 2021, -576 million yuan in 2022, -801 million yuan in 2023, and -797 million yuan in 2024 [2] - For the first three quarters of 2025, Zhixiang Jintai achieved an operating income of 20.8 million yuan, a significant increase of 1,562.05%, but still reported a net loss attributable to shareholders of -333 million yuan [2] - The net cash flow from operating activities for the company was -261 million yuan [2]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Zhixiang Jintai (688443.SH) announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration, indicating a significant step forward in its development for treating adult patients with relapsed or refractory multiple myeloma [1] Group 1 - The product GR1803 is intended for adult patients who have previously undergone at least three lines of treatment, including one proteasome inhibitor, one immunomodulator, and one anti-CD38 monoclonal antibody [1]

重庆智翔金泰生物制药股份有限公司 自愿披露关于GR1803注射液纳入优先审评品种 名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）产品 GR1803 注射液被国家药品监督管理局药品审评中心纳入优先审评品种名单，现 将相关情况公告如下： 一、药品基本信息 证券代码：688443 证券简称：智翔金泰 公告编号：2026-002 药品名称：GR1803 注射液 申请人：重庆智翔金泰生物制药股份有限公司 申请日期：2025 年 12 月 26 日 公示日期：2025 年 12 月 29 日 受理号：CXSS2600003 拟定适应症（或功能主治）：本品适用于既往至少接受过三线治疗（包括一 种蛋白酶体抑制剂、一种免疫调节剂和一种抗 CD38 单克隆抗体）的复发或难治 性多发性骨髓瘤成人患者。 优先审评理由：经审核，本申请符合《药品注册管理办法》和《国家药监局 关于发布〈突破性治疗药物审评工作程序（试行）〉等三个文件的公告》（2020 年第 82 号）有关要求，同意按优 ...

Core Viewpoint - The company Zhixiang Jintai announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration, targeting adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of treatment [1] Group 1 - GR1803 injection is a bispecific antibody drug developed independently by the company, classified as a Class 1 therapeutic biological product [1] - The new drug application still needs to go through multiple stages, and there is uncertainty regarding the product's successful market launch and the timeline for its availability [1]

Core Viewpoint - The company announced that its product GR1803 injection has been included in the priority review list by the National Medical Products Administration's Drug Evaluation Center [1] Group 1 - GR1803 injection is a bispecific antibody drug independently developed by the company [1] - The drug targets BCMA and CD3 [1] - It is classified as a Class 1 therapeutic biological product [1]

Group 1 - The biopharmaceutical sector increased by 1.73% on January 9, with Zhixiang Jintai leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Zhixiang Jintai rising by 11.17% to a closing price of 32.44 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 144 million yuan from institutional investors, while retail investors saw a net inflow of 90.72 million yuan [2] - Major stocks like Wozhen Bio and Wanze Co. had notable net inflows from institutional investors, with Wozhen Bio seeing 108 million yuan [3] - Retail investors showed a net outflow in several stocks, indicating a mixed sentiment in the market [3]